Triple
T20061766
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | BEACOPP regimen |
E499491
|
entity |
| Predicate | hasVariant |
P455
|
FINISHED |
| Object | escalated-dose BEACOPP |
—
|
NE NERFINISHED |
How this triple was built (3 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: escalated-dose BEACOPP | Statement: [BEACOPP regimen, hasVariant, escalated-dose BEACOPP]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: escalated-dose BEACOPP Context triple: [BEACOPP regimen, hasVariant, escalated-dose BEACOPP]
-
A.
standard BEACOPP
Standard BEACOPP is an intensive multi-drug chemotherapy regimen primarily used to treat advanced-stage Hodgkin lymphoma.
-
B.
BEACOPP regimen
The BEACOPP regimen is an intensive multi-drug chemotherapy protocol used primarily for advanced-stage Hodgkin lymphoma.
-
C.
R-CHOP
R-CHOP is a standard chemotherapy regimen combining rituximab with multiple cytotoxic drugs, commonly used to treat non-Hodgkin lymphoma.
-
D.
ABVD regimen
The ABVD regimen is a standard chemotherapy combination used as first-line treatment for classical Hodgkin lymphoma.
-
E.
MOPP chemotherapy regimen
The MOPP chemotherapy regimen is an early combination cancer treatment protocol, historically used for Hodgkin lymphoma, that includes multiple cytotoxic drugs administered in cycles.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: escalated-dose BEACOPP Target entity description: Escalated-dose BEACOPP is an intensified chemotherapy regimen used primarily for treating advanced-stage Hodgkin lymphoma, featuring higher doses of the standard BEACOPP drug combination to improve disease control.
-
A.
standard BEACOPP
Standard BEACOPP is an intensive multi-drug chemotherapy regimen primarily used to treat advanced-stage Hodgkin lymphoma.
-
B.
BEACOPP regimen
The BEACOPP regimen is an intensive multi-drug chemotherapy protocol used primarily for advanced-stage Hodgkin lymphoma.
-
C.
R-CHOP
R-CHOP is a standard chemotherapy regimen combining rituximab with multiple cytotoxic drugs, commonly used to treat non-Hodgkin lymphoma.
-
D.
ABVD regimen
The ABVD regimen is a standard chemotherapy combination used as first-line treatment for classical Hodgkin lymphoma.
-
E.
MOPP chemotherapy regimen
The MOPP chemotherapy regimen is an early combination cancer treatment protocol, historically used for Hodgkin lymphoma, that includes multiple cytotoxic drugs administered in cycles.
- F. None of above. chosen
Provenance (2 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69da6276bcf48190aabbf279192a5fb4 |
completed | April 11, 2026, 3:02 p.m. |
| NER | Named-entity recognition | batch_69e6637601dc8190a07fc20844093cb7 |
completed | April 20, 2026, 5:33 p.m. |
Created at: April 11, 2026, 3:38 p.m.